Merck announces further positive data for its investigational 15-valent pneumococcal conjugate vaccine (V114)

In PNEU-AGE (healthy adults ≥50), V114 was non-inferior to the 13-valent vaccine for the 13 serotypes targeted by both and superior for 22F and 33F (targeted only by V114). In PNEU-TRUE, equivalent immune response across all serotypes was seen for three different lots.


Biospace Inc.